Tags: ms + clinical trial.with.MS

Sort by: Date / Title / URL

1. BioMS shares drop 90 percent on disappointing MS result
   Shares of BioMS Medical Corp (MS.TO: Quote) plunged 90 percent on Tuesday after the company and Eli Lilly and Co (LLY.N: Quote) said their multiple sclerosis treatment failed to delay the progression of the disease in a late-stage trial.
   29-07-2009 to canada, clinical trial, ms, multiple sclerosis, research, spms by admin
2. BBC NEWS | Health | Blood pressure drug hope for MS
   A drug which has been used for decades to treat high blood pressure may turn out to be a key treatment for multiple sclerosis, say British researchers.
   27-11-2007 to amiloride, clinical trial, drugs, ms, multiple sclerosis, uk by admin
3. PharmaLive: BioMS Medical's Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
   The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS.
   25-07-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, relapsing remitting, rrms by admin
4. PharmaLive: Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
   The MS-F204 study, which is conducted under a Special Protocol Assessment (SPA) issued by the Food and Drug Administration (FDA), will evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS.
   07-06-2007 to clinical trial, drug company, drugs, fampridine, ms, multiple sclerosis by admin
5. BioMS Medical initiates enrollment in pivotal U.S. phase III multiple sclerosis trial
   the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis
   07-06-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, spms by admin
6. Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
   THE WOODLANDS, TX, USA | May 17, 2007 | Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced the completion of patient enrollment in a 150-patient Phase IIb safety and effic
   20-05-2007 to clinical trial, ms, multiple sclerosis, relapsing remitting, rrms, tovaxin, us by admin

First / Previous / Next / Last / Page 1 of 1